Treatment with Nomacopan (Coversin) in three patients with mild-to-moderate bullous pemphigoid resulted in no drug-related adverse events and rapid reduction in …
Akari Therapeutics to Provide Update on its Eye Disease Program During Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Poster to be presented on back-of-the-eye program including data from uveitis preclinical modelInterim data expected from Akari’s Phase I/II clinical trial in …
Positive FDA Meeting Outlines Path Ahead for Akari Therapeutics’s Coversin in Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)
HSCT-TMA trial in pediatric patients expected to start Q4 2019 following recent FDA feedback NEW YORK and LONDON, March 13, 2019 – Akari Therapeutics, Plc …
Akari Announces Coversin Data to be Presented at 2018 Complement-Based Drug Development Summit
Highlights potential role of both complement and leukotriene pathways in a therapeutic mouse model of rheumatoid arthritis (RA) NEW YORK and LONDON, November …
Akari Announces Third Quarter 2018 Financial Results and Business Highlights
Four ongoing clinical trial programs Two clinical programs expected to report initial data in first quarter 2019 Long-term clinical study continues to …
[Read more...] about Akari Announces Third Quarter 2018 Financial Results and Business Highlights
